Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Stock Competitors & Peer Comparison

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, VRTX has a market cap of 133.5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while VRTX trades at $526.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas VRTX's P/E ratio is 27.65. In terms of profitability, NBIX's ROE is +0.21%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, NBIX is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check VRTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, REGN has a market cap of 81.2B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while REGN trades at $788.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas REGN's P/E ratio is 17.27. In terms of profitability, NBIX's ROE is +0.21%, compared to REGN's ROE of +0.14%. Regarding short-term risk, NBIX is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check REGN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, MRNA has a market cap of 78.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while MRNA trades at $198.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas MRNA's P/E ratio is -24.40. In terms of profitability, NBIX's ROE is +0.21%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, NBIX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check MRNA's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas VRNA's P/E ratio is -102.80. In terms of profitability, NBIX's ROE is +0.21%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, NBIX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check VRNA's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ARGX has a market cap of 59.7B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ARGX trades at $959.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ARGX's P/E ratio is 34.60. In terms of profitability, NBIX's ROE is +0.21%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, NBIX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ARGX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, RVMDW has a market cap of 44.7B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while RVMDW trades at $11.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas RVMDW's P/E ratio is -1.29. In terms of profitability, NBIX's ROE is +0.21%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, NBIX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check RVMDW's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, RVMD has a market cap of 43.6B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while RVMD trades at $204.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas RVMD's P/E ratio is -23.24. In terms of profitability, NBIX's ROE is +0.21%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, NBIX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check RVMD's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas SGEN's P/E ratio is -57.19. In terms of profitability, NBIX's ROE is +0.21%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, NBIX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check SGEN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ONC has a market cap of 38.6B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ONC trades at $360.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ONC's P/E ratio is 63.53. In terms of profitability, NBIX's ROE is +0.21%, compared to ONC's ROE of +0.14%. Regarding short-term risk, NBIX is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ONC's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ALNY has a market cap of 34.2B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ALNY trades at $255.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ALNY's P/E ratio is 46.12. In terms of profitability, NBIX's ROE is +0.21%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, NBIX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ALNY's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ROIV has a market cap of 25.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ROIV trades at $35.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ROIV's P/E ratio is -34.06. In terms of profitability, NBIX's ROE is +0.21%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, NBIX is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ROIV's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, INSM has a market cap of 25.5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while INSM trades at $117.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas INSM's P/E ratio is -28.67. In terms of profitability, NBIX's ROE is +0.21%, compared to INSM's ROE of -1.11%. Regarding short-term risk, NBIX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check INSM's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, INCY has a market cap of 25.1B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while INCY trades at $123.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas INCY's P/E ratio is 16.65. In terms of profitability, NBIX's ROE is +0.21%, compared to INCY's ROE of +0.30%. Regarding short-term risk, NBIX is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check INCY's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, BNTX has a market cap of 24.7B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while BNTX trades at $98.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas BNTX's P/E ratio is -12.78. In terms of profitability, NBIX's ROE is +0.21%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, NBIX is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check BNTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, GMAB has a market cap of 21.7B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while GMAB trades at $35.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas GMAB's P/E ratio is 26.62. In terms of profitability, NBIX's ROE is +0.21%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, NBIX is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check GMAB's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas BGNE's P/E ratio is -22.55. In terms of profitability, NBIX's ROE is +0.21%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, NBIX is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check BGNE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, UTHR has a market cap of 20.2B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while UTHR trades at $475.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas UTHR's P/E ratio is 17.01. In terms of profitability, NBIX's ROE is +0.21%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, NBIX is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check UTHR's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, NBIX's ROE is +0.21%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, NBIX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check DNA-WT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, JAZZ has a market cap of 14.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while JAZZ trades at $237.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas JAZZ's P/E ratio is 8.87. In terms of profitability, NBIX's ROE is +0.21%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, NBIX is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check JAZZ's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, EXEL has a market cap of 14.6B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while EXEL trades at $58.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas EXEL's P/E ratio is 16.62. In terms of profitability, NBIX's ROE is +0.21%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, NBIX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check EXEL's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ASND has a market cap of 14B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ASND trades at $225.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ASND's P/E ratio is -93.22. In terms of profitability, NBIX's ROE is +0.21%, compared to ASND's ROE of +1.90%. Regarding short-term risk, NBIX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ASND's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, HALO has a market cap of 13.5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while HALO trades at $113.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas HALO's P/E ratio is 21.25. In terms of profitability, NBIX's ROE is +0.21%, compared to HALO's ROE of +1.81%. Regarding short-term risk, NBIX is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check HALO's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, BBIO has a market cap of 12.8B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while BBIO trades at $65.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas BBIO's P/E ratio is -17.53. In terms of profitability, NBIX's ROE is +0.21%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, NBIX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check BBIO's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas KRTX's P/E ratio is -28.09. In terms of profitability, NBIX's ROE is +0.21%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, NBIX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check KRTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, SMMT has a market cap of 12.5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while SMMT trades at $15.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas SMMT's P/E ratio is -13.94. In terms of profitability, NBIX's ROE is +0.21%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, NBIX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check SMMT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while MDGL trades at $516.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas MDGL's P/E ratio is -40.36. In terms of profitability, NBIX's ROE is +0.21%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, NBIX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check MDGL's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while BMRN trades at $60.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas BMRN's P/E ratio is 28.97. In terms of profitability, NBIX's ROE is +0.21%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, NBIX is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check BMRN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, TWST has a market cap of 11.4B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while TWST trades at $182.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas TWST's P/E ratio is -82.44. In terms of profitability, NBIX's ROE is +0.21%, compared to TWST's ROE of -0.30%. Regarding short-term risk, NBIX is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check TWST's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while TECH trades at $72.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas TECH's P/E ratio is 37.43. In terms of profitability, NBIX's ROE is +0.21%, compared to TECH's ROE of +0.09%. Regarding short-term risk, NBIX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check TECH's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas RNAM's P/E ratio is -17.39. In terms of profitability, NBIX's ROE is +0.21%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, NBIX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check RNAM's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, TXG has a market cap of 10.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while TXG trades at $85.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas TXG's P/E ratio is -145.27. In terms of profitability, NBIX's ROE is +0.21%, compared to TXG's ROE of -0.09%. Regarding short-term risk, NBIX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check TXG's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, KRYS has a market cap of 10.2B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while KRYS trades at $345.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas KRYS's P/E ratio is 43.34. In terms of profitability, NBIX's ROE is +0.21%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, NBIX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check KRYS's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, AXSM has a market cap of 10B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while AXSM trades at $195.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas AXSM's P/E ratio is -50.94. In terms of profitability, NBIX's ROE is +0.21%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, NBIX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check AXSM's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas RXDX's P/E ratio is -56.47. In terms of profitability, NBIX's ROE is +0.21%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, NBIX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check RXDX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ARWR has a market cap of 9.3B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ARWR trades at $65.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ARWR's P/E ratio is -29.30. In terms of profitability, NBIX's ROE is +0.21%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, NBIX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ARWR's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, KYMR has a market cap of 9.2B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while KYMR trades at $111.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas KYMR's P/E ratio is -34.98. In terms of profitability, NBIX's ROE is +0.21%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, NBIX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check KYMR's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas NUVL's P/E ratio is -21.79. In terms of profitability, NBIX's ROE is +0.21%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, NBIX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check NUVL's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, PTGX has a market cap of 9.1B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while PTGX trades at $141.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas PTGX's P/E ratio is 137.73. In terms of profitability, NBIX's ROE is +0.21%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, NBIX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check PTGX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, CAI has a market cap of 9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while CAI trades at $31.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas CAI's P/E ratio is 89.86. In terms of profitability, NBIX's ROE is +0.21%, compared to CAI's ROE of +0.19%. Regarding short-term risk, NBIX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check CAI's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas CRNX's P/E ratio is -16.86. In terms of profitability, NBIX's ROE is +0.21%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, NBIX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check CRNX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, IBRX has a market cap of 8.8B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while IBRX trades at $8.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas IBRX's P/E ratio is -8.70. In terms of profitability, NBIX's ROE is +0.21%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, NBIX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check IBRX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, TGTX has a market cap of 8.8B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while TGTX trades at $57.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas TGTX's P/E ratio is 20.81. In terms of profitability, NBIX's ROE is +0.21%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, NBIX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check TGTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas IMGN's P/E ratio is -111.55. In terms of profitability, NBIX's ROE is +0.21%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, NBIX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check IMGN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas BPMC's P/E ratio is -51.58. In terms of profitability, NBIX's ROE is +0.21%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, NBIX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check BPMC's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas APGE's P/E ratio is -31.19. In terms of profitability, NBIX's ROE is +0.21%, compared to APGE's ROE of -0.30%. Regarding short-term risk, NBIX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check APGE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas CERE's P/E ratio is -16.47. In terms of profitability, NBIX's ROE is +0.21%, compared to CERE's ROE of -0.72%. Regarding short-term risk, NBIX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check CERE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, PCVX has a market cap of 8.1B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while PCVX trades at $56.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas PCVX's P/E ratio is -7.37. In terms of profitability, NBIX's ROE is +0.21%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, NBIX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check PCVX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, CYTK has a market cap of 8B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while CYTK trades at $64.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas CYTK's P/E ratio is -8.96. In terms of profitability, NBIX's ROE is +0.21%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, NBIX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check CYTK's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, PRAX has a market cap of 7.8B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while PRAX trades at $280.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas PRAX's P/E ratio is -21.72. In terms of profitability, NBIX's ROE is +0.21%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, NBIX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check PRAX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, SYRE has a market cap of 7.4B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while SYRE trades at $85.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas SYRE's P/E ratio is -43.94. In terms of profitability, NBIX's ROE is +0.21%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, NBIX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check SYRE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas MTSR's P/E ratio is -23.58. In terms of profitability, NBIX's ROE is +0.21%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, NBIX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check MTSR's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, IONS has a market cap of 7.4B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while IONS trades at $44.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas IONS's P/E ratio is -13.61. In terms of profitability, NBIX's ROE is +0.21%, compared to IONS's ROE of -1.11%. Regarding short-term risk, NBIX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check IONS's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while IMVT trades at $33.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas IMVT's P/E ratio is -11.81. In terms of profitability, NBIX's ROE is +0.21%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, NBIX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check IMVT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas MRUS's P/E ratio is -17.05. In terms of profitability, NBIX's ROE is +0.21%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, NBIX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check MRUS's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while RYTM trades at $98.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas RYTM's P/E ratio is -31.72. In terms of profitability, NBIX's ROE is +0.21%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, NBIX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check RYTM's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ACLX's P/E ratio is -28.27. In terms of profitability, NBIX's ROE is +0.21%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, NBIX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ACLX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while BLTE trades at $167.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas BLTE's P/E ratio is -89.48. In terms of profitability, NBIX's ROE is +0.21%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, NBIX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check BLTE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ABVX has a market cap of 6.7B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ABVX trades at $91.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ABVX's P/E ratio is -17.33. In terms of profitability, NBIX's ROE is +0.21%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, NBIX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ABVX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas RETA's P/E ratio is -66.29. In terms of profitability, NBIX's ROE is +0.21%, compared to RETA's ROE of +0.47%. Regarding short-term risk, NBIX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check RETA's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas CNTA's P/E ratio is -22.63. In terms of profitability, NBIX's ROE is +0.21%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, NBIX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check CNTA's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, LGND has a market cap of 6B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while LGND trades at $301.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas LGND's P/E ratio is 33.10. In terms of profitability, NBIX's ROE is +0.21%, compared to LGND's ROE of +0.20%. Regarding short-term risk, NBIX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check LGND's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while CGON trades at $67.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas CGON's P/E ratio is -24.96. In terms of profitability, NBIX's ROE is +0.21%, compared to CGON's ROE of -0.25%. Regarding short-term risk, NBIX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check CGON's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while SRRK trades at $48.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas SRRK's P/E ratio is -14.10. In terms of profitability, NBIX's ROE is +0.21%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, NBIX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check SRRK's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas CDTX's P/E ratio is -19.77. In terms of profitability, NBIX's ROE is +0.21%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, NBIX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check CDTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, TVTX has a market cap of 5.5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while TVTX trades at $59.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas TVTX's P/E ratio is -132.09. In terms of profitability, NBIX's ROE is +0.21%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, NBIX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check TVTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, NBIX's ROE is +0.21%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, NBIX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ABCM's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while COGT trades at $32.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas COGT's P/E ratio is -15.31. In terms of profitability, NBIX's ROE is +0.21%, compared to COGT's ROE of -0.73%. Regarding short-term risk, NBIX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check COGT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ISEE's P/E ratio is -22.44. In terms of profitability, NBIX's ROE is +0.21%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, NBIX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ISEE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, MIRM has a market cap of 5.5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while MIRM trades at $89.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas MIRM's P/E ratio is -6.16. In terms of profitability, NBIX's ROE is +0.21%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, NBIX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check MIRM's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas APLS's P/E ratio is 38.35. In terms of profitability, NBIX's ROE is +0.21%, compared to APLS's ROE of +0.40%. Regarding short-term risk, NBIX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check APLS's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, PTCT has a market cap of 5.2B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while PTCT trades at $62.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas PTCT's P/E ratio is -26.90. In terms of profitability, NBIX's ROE is +0.21%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, NBIX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check PTCT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while CRSP trades at $54.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas CRSP's P/E ratio is -11.39. In terms of profitability, NBIX's ROE is +0.21%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, NBIX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check CRSP's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ORKA has a market cap of 5.1B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ORKA trades at $84.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ORKA's P/E ratio is -43.54. In terms of profitability, NBIX's ROE is +0.21%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, NBIX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ORKA's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, DNTH has a market cap of 5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while DNTH trades at $88.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas DNTH's P/E ratio is -21.34. In terms of profitability, NBIX's ROE is +0.21%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, NBIX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check DNTH's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ERAS has a market cap of 4.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ERAS trades at $14.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ERAS's P/E ratio is -15.32. In terms of profitability, NBIX's ROE is +0.21%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, NBIX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ERAS's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, IOVA has a market cap of 4.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while IOVA trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas IOVA's P/E ratio is -15.07. In terms of profitability, NBIX's ROE is +0.21%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, NBIX is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check IOVA's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while MANE trades at $116.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas MANE's P/E ratio is -37.15. In terms of profitability, NBIX's ROE is +0.21%, compared to MANE's ROE of -0.38%. Regarding short-term risk, NBIX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check MANE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, DFTX has a market cap of 4.8B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while DFTX trades at $36.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas DFTX's P/E ratio is N/A. In terms of profitability, NBIX's ROE is +0.21%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, NBIX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check DFTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas TERN's P/E ratio is -51.41. In terms of profitability, NBIX's ROE is +0.21%, compared to TERN's ROE of -0.20%. Regarding short-term risk, NBIX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check TERN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ADPT has a market cap of 4.7B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ADPT trades at $29.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ADPT's P/E ratio is -71.78. In terms of profitability, NBIX's ROE is +0.21%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, NBIX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ADPT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas FOLD's P/E ratio is -161.00. In terms of profitability, NBIX's ROE is +0.21%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, NBIX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check FOLD's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas AKRO's P/E ratio is -14.57. In terms of profitability, NBIX's ROE is +0.21%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, NBIX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check AKRO's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ALPN's P/E ratio is -101.52. In terms of profitability, NBIX's ROE is +0.21%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, NBIX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ALPN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas OPT's P/E ratio is -1.52. In terms of profitability, NBIX's ROE is +0.21%, compared to OPT's ROE of +1.18%. Regarding short-term risk, NBIX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check OPT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while EWTX trades at $39.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas EWTX's P/E ratio is -21.26. In terms of profitability, NBIX's ROE is +0.21%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, NBIX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check EWTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas PRTC's P/E ratio is -3.78. In terms of profitability, NBIX's ROE is +0.21%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, NBIX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check PRTC's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while VKTX trades at $35.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas VKTX's P/E ratio is -7.63. In terms of profitability, NBIX's ROE is +0.21%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, NBIX is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check VKTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas MRTX's P/E ratio is -4.82. In terms of profitability, NBIX's ROE is +0.21%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, NBIX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check MRTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, TNGX has a market cap of 4.1B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while TNGX trades at $24.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas TNGX's P/E ratio is -30.02. In terms of profitability, NBIX's ROE is +0.21%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, NBIX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check TNGX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, TLX has a market cap of 3.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while TLX trades at $11.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas TLX's P/E ratio is 119.52. In terms of profitability, NBIX's ROE is +0.21%, compared to TLX's ROE of +0.07%. Regarding short-term risk, NBIX is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check TLX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ABCL trades at $12.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ABCL's P/E ratio is -23.52. In terms of profitability, NBIX's ROE is +0.21%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, NBIX is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ABCL's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, CELC has a market cap of 3.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while CELC trades at $79.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas CELC's P/E ratio is -18.49. In terms of profitability, NBIX's ROE is +0.21%, compared to CELC's ROE of -3.51%. Regarding short-term risk, NBIX is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check CELC's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas CPRX's P/E ratio is 17.49. In terms of profitability, NBIX's ROE is +0.21%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, NBIX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check CPRX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, RLAY has a market cap of 3.8B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while RLAY trades at $17.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas RLAY's P/E ratio is -11.13. In terms of profitability, NBIX's ROE is +0.21%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, NBIX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check RLAY's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas RYZB's P/E ratio is -57.86. In terms of profitability, NBIX's ROE is +0.21%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, NBIX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check RYZB's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas CBAY's P/E ratio is -32.81. In terms of profitability, NBIX's ROE is +0.21%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, NBIX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check CBAY's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, PBLS has a market cap of 3.6B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while PBLS trades at $31.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas PBLS's P/E ratio is -16.60. In terms of profitability, NBIX's ROE is +0.21%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, NBIX is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check PBLS's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, XENE has a market cap of 3.6B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while XENE trades at $36.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas XENE's P/E ratio is -7.86. In terms of profitability, NBIX's ROE is +0.21%, compared to XENE's ROE of -0.44%. Regarding short-term risk, NBIX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check XENE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 13.9B. In comparison, ACAD has a market cap of 3.5B. Regarding current trading prices, NBIX is priced at $138.40 on the NASDAQ, while ACAD trades at $20.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 19.96, whereas ACAD's P/E ratio is 9.32. In terms of profitability, NBIX's ROE is +0.21%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, NBIX is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ACAD's competition here